TRACT Therapeutics believes that the Company’s product candidates consisting of T regulatory cells (Tregs) generated ex-vivo from patient’s blood will offer great promise to the health care system and to the many Americans facing organ transplantation and autoimmune disease. This breakthrough technology for self-regulation of the immune system has come to be recognized as an attractive way to promote transplantation tolerance and prevent rejection of transplanted organs. Everyday our team is dedicated to improving patient’s lives.
The technology is a cell-based biologic, that when expanded in the laboratory and re-introduced back into the patient, suppresses the patient’s immune response to the transplanted organ, preventing its rejection.
TRACT (Treg Adoptive Cell Transfer) involves the isolation and expansion of a patient’s own naturally occurring T regulatory cells, known as Tregs. Tregs have been shown to modulate immune responses and significantly contribute to immune system tolerance. Tregs represent a critical pathway through which the immune system can actively down-regulate immune responses.
The Treatment Process
The TRACT process begins when a patient in need of an organ transplant undergoes a pre-transplant blood donation. The white blood cells (which include Tregs) are cryopreserved in the laboratory using a proprietary process. After the patient receives the organ transplant, the cryopreserved cells are thawed, isolated, and expanded until enough Tregs are generated for administration back into the patient. Once infused, the expanded Tregs traffic to critical areas of immune engagement to down regulate transplant rejection and reduce or prevent inflammation. The Company has completed a Phase I clinical trial to determine the safety of Treg administration in kidney transplant patients. Subsequently, the Company will evaluate the clinical efficacy of Tregs in establishing immune tolerance and preventing organ rejection.
The process is simple:
- Transplant candidate provides blood donation
- White blood cells (WBCs), which Include T-regulatory cells are cryopreserved
- After organ transplantation, technicians thaw WBCs, isolate and expand cells
- Expanded T-regulatory cells are re-infused into the patient